Organigram Reports Fourth Quarter Fiscal 2021 Results – MJ Stock TraderOrganigram Reports Fourth Quarter Fiscal 2021 Results – MJ Stock Trader

November 26, 2021

Continued growth in net revenue and increased market share

Achieved a 7% share of market in the recreational cannabis market in Q4, up from 5.4% in Q3 2021, positioning Organigram as the #4 licensed producer and the momentum continues with a 7.9% share of market as of October.1
24% growth in gross revenue to $36.2 million in Q4 2021 from Q3 2021 and 43% from the same prior-year period
22% growth in net revenue to $24.9 million in Q4 2021 from Q3 2021 and 22% from the same prior-year period
36% growth in recreational net revenue to $22.9 million in Q4 2021 from Q3 2021 and 52% from the same prior-year period
Launched 16 new stock-keeping units (SKUs) in the recreational channel
SHRED was the #1 most-searched brand on the Ontario Cannabis Store website (OCS.ca) for 11 out of the last 12 months. 2
Launched Edison JOLTS, an ingestible extract lozenge that is the #1 SKU 3 in its category
Launched SHRED’ems cannabis-infused gummies in early August which have quickly gained momentum, reaching a 5.8%4 market share of the gummy category
Unrestricted cash and short-term investment balance of $172 million and debt of $0.3 million, ensures the Company is well-resourced to execute its growth strategy

November 23, 2021 06:00 AM Eastern Standard Time

MONCTON, New Brunswick–(BUSINESS WIRE)–Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced its results for the fourth quarter ended August 31, 2021 (“Q4 Fiscal 2021”).

“The results in Q4 Fiscal 2021 demonstrate the momentum we have achieved from our efforts to lead innovation and increase efficiencies. In the quarter, we introduced exciting new products that were embraced by consumers and we achieved higher crop yields at a lower cost”Tweet this

“The results in Q4 Fiscal 2021 demonstrate the momentum we have achieved from our efforts to lead innovation and increase efficiencies. In the quarter, we introduced exciting new products that were embraced by consumers and we achieved higher crop yields at a lower cost” said Beena Goldenberg, Chief Executive Officer. “We are particularly pleased with our market share gains in the quarter to become a #4 LP and will build on these successes into Fiscal 2022.”

Ms. Goldenberg concluded, “We are excited for what Fiscal 2022 holds for Organigram. Looking ahead, we expect to continue our momentum as we maintain our focus on increased points of distribution, bringing new, impactful and innovative products such as Edison Jolts, SHRED and SHRED’ems to market, and improve our ability to fulfill the growing demand for our products.”

Select Key Financial Metrics (in $000s unless otherwise indicated)
Q4-2021
Q4-2020
% Change

Gross revenue
36,182
 
25,389
 
43
%

Excise taxes
(11,317
)
(4,989
)
127
%

Net revenue
24,865
 
20,400
 
22
%

Cost of sales
25,867
 
29,007
 
(11
)%

Gross margin before fair value changes to biological assets & inventories sold
(1,002
)
(8,607
)
(88
)%

Fair value changes to biological assets & inventories sold
4,353
 
(20,149
)
(122
)%

Gross margin
3,351
 
(28,756
)
(112
)%

Adjusted gross margin*
3,017
 
6,156
 
(51
)%

Adjusted gross margin %*
12
%
30
%
(60
)%

Selling (including marketing), general & administrative expenses**
13,562
 
10,830
 
25
%

Adjusted EBITDA*
(4,818
)
(2,320
)
(108
)%

Net loss
(25,971
)
(38,590
)
(33
)%

Net cash used in operating activities
(7,699
)
(7,676
)

%

* Adjusted gross margin, adjusted gross margin % and adjusted EBITDA are non-IFRS financial measures not defined by and do not have any standardized meaning under IFRS; please refer to the Company’s Q4 Fiscal 2021 MD&A for definitions and a reconciliation to IFRS. 
** Excluding non-cash share-based compensation.

Select Balance Sheet Metrics (in $000s)
AUGUST 
31, 2021
AUGUST 
31, 2020
% Change

Cash & short-term investments
183,555
 
74,728
 
146
%

Biological assets & inventories
48,818
 
71,759
 
(32
)%

Other current assets
28,242
 
23,717
 
19
%

Accounts payable & accrued liabilities
23,436
 
17,486
 
34
%

Current portion of long-term debt
80
 
11,595
 
(99
)%

Working capital
234,349
 
141,123
 
66
%

Property, plant & equipment
235,939
 
247,420
 
(5
)%

Long-term debt
230
 
103,671
 
(100
)%

Total assets
554,017
 
435,127
 
27
%

Total liabilities
74,212
 
135,600
 
(45
)%

Shareholders’ equity
479,805
 
299,527
 
60
%

“We move into Fiscal 2022 with a robust balance sheet that provides us with the ability to fund important growth initiatives such as the CoE we have launched with BAT. This will allow us to continue our advances in product development and plant science and drive revenue growth,” added Derrick West, Chief Financial Officer. “We will also continue to invest in our facilities to create economies of scale and cost efficiencies that will further improve our gross margin profile.”

Key Financial Results for the Fourth Quarter Fiscal 2021

Net revenue:

Compared to the prior year, net revenue increased 22% to $24.9 million, from $20.4 million in Q4 Fiscal 2020. The increase was primarily due to an increase in adult-use recreational revenue, partly offset by the decrease in international revenue, medical revenue, wholesale revenue to other Licensed Producers and a lower average net selling price (“ASP”).

Cost of sales:

Q4 Fiscal 2021 cost of sales decreased by 11% to $25.9 million, from $29.0 million in Q4 Fiscal 2020. The decrease was primarily due to the current quarter’s reduction to inventory write-offs and provisions, along with reductions to the fixed unabsorbed overhead expenses.

Gross margin before fair value changes to biological assets, inventories sold, and other charges:

Gross margin improved in Q4 Fiscal 2021 from Q4 Fiscal 2020 largely due to higher net revenue and lower cost of sales as described above.

Gross margin:

Q4 2021 gross margin increased to a positive result from negative Q4 2020 gross margin largely due to higher Q4 2021 gross margin before fair value changes to biological assets and inventories sold as described above, as well as net non-cash positive fair value changes to biological assets and inventories sold in Q4 2021 versus negative changes in Q4 2020.

Adjusted gross margin5:

Q4 Fiscal 2021 adjusted gross margin was $3.0 million, or 12% of net revenue, compared to a negative $0.7 million, or 4%, negative adjusted gross margin during the preceding quarter (Q3 Fiscal 2021). This improvement during the current quarter was largely due to higher net revenues combined with lower cost of sales that was as a direct result of the lower costs of production.

Selling, general & administrative (SG&A) expenses:

Q4 Fiscal 2021 SG&A expenses increased by 26% to $13.6 million from Q4 Fiscal 2020, primarily due to increased audit fees and general office expenses in connection with the CoE, such CoE expenses being equally shared with BAT. Sales and marketing expenses increased mainly due to data licensing fees that increased as a result of the continued rollout of stores in Ontario, combined with marketing initiatives related to the launch of the Company’s gummy products and an increased focus on our Edison flagship brand.

Adjusted EBITDA6:

Q4 Fiscal 2021 negative adjusted EBITDA decreased 48% from $9.2 million in Q3 2021 to $4.8 million. This improvement was primarily attributed to the increase in revenues and the improved adjusted gross margin.

Net loss:

Q4 Fiscal 2021 net loss was reduced to $26.0 million, compared to a net loss of $38.6 million in Q4 Fiscal 2020, largely due to the higher gross margin in Q4 Fiscal 2021 described above which were partially offset by the impairment charges during the current quarter.

Net cash used in operating activities:

Q4 Fiscal 2021 net cash used in operating activities of $7.7 million was the same as the prior year’s comparison quarter. The current period’s deficiency was largely due to the quarter’s adjusted EBITDA deficit.

Canadian Recreational Market

Launch of Cannabis Innovators Panel

In July 2021, Organigram launched the Cannabis Innovators Panel, a cannabis consumer panel offering real-time insights into consumer preferences, usage occasions, and future development opportunities. This online panel will engage with hundreds of participants across Canada on an ongoing basis. The panel will contribute feedback on both existing product categories and guide areas of future research and development, including flower, vapes, concentrates, edibles, and pre-rolls.

SHRED’ems, cannabis-infused gummies

SHRED’ems cannabis-infused gummies, are an extension of Organigram’s highly popular, value-priced SHRED brand, launched to capitalize on the existing equity of SHRED and satisfy the need for value priced, high quality gummies. Since its launch in early August 2021, SHRED’ems has quickly gained momentum, capturing a 5.8% national retail market share as of November 17, 2021.4

Edison JOLTS high potency THC lozenges

Launched in August 2021, Edison JOLTS are mint flavoured, high potency THC lozenges that combine the benefits of sublingual oil with the convenience and portability of soft gels. Each package contains an unprecedented 100mg of THC. JOLTS has quickly achieved the top-selling position as the #1 LP ranking within ingestible extracts.3

Monjour CBD-forward wellness brand

Most recently, Organigram launched Monjour, a new CBD-forward wellness brand dedicated to the pursuit of a daily wellness regime. Monjour’s four initial SKUs will be shipping to stores across Canada throughout November and are available in both vegan and sugar-free options. Monjour offers 600mg of CBD/package.

Research and Product Development 
Centre of Excellence (“CoE”)

In early Q4 Fiscal 2021, the Company announced the successful launch of the CoE, outlined in the agreement with BAT, which was established to focus on research and product development activities for the next generation of cannabis products, as well as cannabinoid fundamental science, with an initial focus on CBD. The CoE is located at the Moncton Campus, which holds the Health Canada licenses required to conduct R&D activities with cannabis products.

The Company and BAT have already created a number of new full-time product development, analytical science and innovation related roles which is expected to ramp up in the second phase of the CoE expansion in Fiscal 2022 when further full time employees will be added.
The CoE includes state of the art shared R&D, Good Production Practices (“GPP”) food preparation, sensory testing and bio-lab research.
To date, the CoE remains on schedule for staffing, construction, and project planning, and the remaining core construction projects are anticipated to be completed by Q2 Fiscal 2022.

Plant Science, Breeding and Genomics R&D in Moncton

Organigram’s cultivation plans focus on cultivating a pipeline of unique and sought-after genetics, maximizing flower quality in terms of THC yield, terpene profiles and general plant health to meet evolving consumer demand. The Company plans to aggressively pursue expanding its in-house breeding program, dedicating significant R&D space for breeding, phenotyping, screening, and various Plant Science Trials while ensuring no competing priorities with commercial cultivation capacity.
As part of its ongoing genetic exploration program, the Company now benefits from leveraging BAT’s tremendous depth of expertise in plant science and Organigram is excited about the developments in progress.
Organigram believes its strategic and creative product development process is a key differentiator for the Edison portfolio and the Company overall and looks forward to introducing more new genetics over the next few quarters.

Outlook7

Net revenue

Organigram currently expects Q1 Fiscal 2022 revenue to be higher than Q4 Fiscal 2021 largely due to: stronger forecasted market growth as COVID-19 restrictions continue to lift and the number of retail stores continues to grow; and the Company is better able to fulfill the demand for its revitalized product portfolio with its increased production.
Net revenue growth is expected from the Company’s products as evidenced by Organigram’s growing national adult-use recreational retail market share (“market share”) from 5.4% in Q3 to 7% in Q4. As of October, the momentum continues and the Company has reached a 7.9% share of market, maintaining its position as the #4 LP in Canada.
In addition, the resumption of shipments to Canndoc in Israel is expected to generate higher sequential revenue in Q1 Fiscal 2022 as compared to Q4 Fiscal 2021. The Company believes it is better equipped to fulfill demand in Q1 Fiscal 2022 with larger harvests expected as compared to Q4 Fiscal 2021. Revenues to date in Q1 Fiscal 2022 including a shipment to Canndoc that was in excess of $3.0 million, and purchase orders received from customers, support the Company’s expectation of revenue growth from Q4 Fiscal 2021 to Q1 Fiscal 2022; however actual results could vary from estimates from the date hereof until year-end.
Organigram also expects to be positioned to generate more revenue growth from the production of soft chews and other edible products with the specialized equipment in the Winnipeg Facility under the direction of EIC leadership, who bring significant expertise in confectionery manufacturing.

Adjusted gross margins

The Company expects to begin to see a sequential improvement in adjusted gross margins in Q1 Fiscal 2022 and has put in place measures that it expects will further improve margins over time.
The overall level of Q1 Fiscal 2022 adjusted gross margins versus Q4 Fiscal 2021 will also be dependent on other factors, including, but not limited to, product category and brand sales mix.
Organigram has identified the following opportunities which it believes have the potential to further improve adjusted gross margins over time:

Economies of scale and efficiencies gained as it continues to scale up cultivation, including the grow rooms that will be available after completing the construction of phase 4c of the Moncton Campus;
Changes to its growing and harvesting methodologies and design improvements and environmental enhancements should improve operating conditions of the Moncton Campus, resulting in higher-quality flower and improved yields;
International sales have historically attracted higher margins and are expected to represent a greater proportion of the Company’s revenue following the resumption of shipments to Canndoc Ltd.;
More sales from 1g Edison vape cartridges that generally attract higher margins;
Continued investment in automation which will drive cost efficiencies and reduce dependence on manual labor;
Price increases to SHRED’s pre-milled flower SKUs;
The recent launches of new products such as Edison Jolts (ingestible extracts), SHRED’ems and most recently Monjour represent new potential avenues of growth with expected attractive long-term margin profiles for the Company.

SG&A Expenses8

Q1 Fiscal 2022 SG&A is expected to be similar to Q4 Fiscal 2021. Starting with Q1 2022, research and development activities will be shown separately from SG&A expenses.

International

Shipments to Canndoc Ltd., which resumed during Q1 Fiscal 2022, are expected to continue during Fiscal 2022.
Recent political changes and cannabis election ballot initiatives for medical and recreational use in the United States suggest that the potential movements to U.S. federal legalization of cannabis (THC) have increased momentum, but the timing and outcome remain difficult to predict. Organigram continues to monitor and develop a potential U.S. THC strategy and evaluate CBD entry opportunities in the United States.

Liquidity and Capital Resources

On August 31, 2021, the Company had unrestricted cash and short-term investments balance of $184 million compared to $75 million at August 31, 2020, an increase of 145%. The increase was primarily as a result of $65 million unit offering done November 2020, $221 million of equity proceeds received from BAT as part of a strategic investment, net of $115 million of monies used during fiscal 2021 towards the repayment of long-term debt and $31 million allocated to restricted funds, to be used directly towards the expenditures of the CoE.
Organigram believes its capital position is healthy and that there is sufficient liquidity available for the near to medium term.

Capital Structure

in $000s
AUGUST 
31, 2021
AUGUST 
31, 2020

Current and long-term debt
310
 
115,266
 

Shareholders’ equity
479,805
 
299,527
 

Total debt and shareholders’ equity
480,115
 
414,793
 

in 000s
 
 

Outstanding common shares
298,786
 
194,511
 

Options
7,797
 
9,264
 

Warrants
16,944
 

 

Top-up rights
6,559
 

 

Restricted share units
1,186
 
912
 

Performance share units
472
 
120
 

Total fully-diluted shares
331,744
 
204,807
 

Outstanding basic and fully diluted share count as at November 19, 2021 is as follows:

in 000s
NOVEMBER 19, 
2021

Outstanding common shares
299,844

Options
8,139

Warrants
16,944

Top-up rights
6,773

Restricted share units
1,566

Performance share units
614

Total fully-diluted shares
333,880

Fourth Quarter Fiscal 2021 Conference Call

The Company will host a conference call to discuss its results with details as follows: 
Date: November 23, 2021 
Time: 8:00am Eastern Time 
To register for the conference call, please use this link: 
http://www.directeventreg.com/registration/event/4654838

To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call. After registering, a confirmation will be sent through email, including dial in details and unique conference call codes for entry. Registration is open through the live call.

To access the webcast: 
https://event.on24.com/wcc/r/3408680/AE5B7A69C202603E882FDF25D0092F3D

A replay of the webcast will be available within 24 hours after the conclusion of the call at https://www.organigram.ca/investorsand will be archived for a period of 90 days following the call.

Non-IFRS Financial Measures

This news release refers to certain financial performance measures (including adjusted gross margin and adjusted EBITDA) that are not defined by and do not have a standardized meaning under International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board. Non-IFRS financial measures are used by management to assess the financial and operational performance of the Company. The Company believes that these non-IFRS financial measures, in addition to conventional measures prepared in accordance with IFRS, enable investors to evaluate the Company’s operating results, underlying performance and prospects in a similar manner to the Company’s management. As there are no standardized methods of calculating these non-IFRS measures, the Company’s approaches may differ from those used by others, and accordingly, the use of these measures may not be directly comparable. Accordingly, these non-IFRS measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. Please refer to the Company’s Q4 Fiscal 2021 MD&A for definitions and, in the case of adjusted EBITDA, a reconciliation to IFRS amounts.

Source link

Share:

Leave a Reply

Your email address will not be published. Required fields are marked *